# Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

> **NCT00329641** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Ciliary Body and Choroid Melanoma, Medium/Large Size
- Extraocular Extension Melanoma
- Iris Melanoma
- Metastatic Intraocular Melanoma
- Recurrent Intraocular Melanoma

## Interventions

- **DRUG:** carboplatin
- **DRUG:** paclitaxel
- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00329641
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2014-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329641, "Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00329641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*